Salveen Richter (Goldman Sachs) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Salveen Richter's stock ratings?

About 51% of Salveen's ratings were profitable over a one-year hold, with an average return of +0.7% per rating, measured by 13Foresight from historical prices.

Q: How is Salveen ranked?

Salveen Richter is ranked #2149 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Salveen Richter

Salveen Richter

Goldman Sachs

Wall Street Analyst

★★☆☆☆

#2149

on 13Foresight · ranked by our own returns

51%

Success Rate

+0.7%

Average Return

34 of 67 calls profitable · -9.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 51% of Salveen Richter's ratings turned a profit when each position was held for 1 year — averaging +0.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

68 Buy 47 Hold 6 Sell

Salveen's Stock Coverage 58 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
QURE uniQure	Jun 17, 2026	HOLD	Strong Buy +16.1% avg upside 29 analysts	$46.00 0.56% Downside	·
MRNA Moderna	Jun 16, 2026	HOLD	Hold +6.1% avg upside 38 analysts	$49.00 23.47% Downside	+15.4%
INCY Incyte	Jun 15, 2026	HOLD	Buy +1.0% avg upside 47 analysts	$100.00 1.85% Upside	-2.9%
AGIO Agios Pharma	Jun 14, 2026	HOLD	Strong Buy +73.2% avg upside 29 analysts	$32.00 6.35% Downside	·
NTLA Intellia Therapeutics	Jun 14, 2026	SELL	Buy +151.9% avg upside 37 analysts	$9.00 42.61% Downside	·
VRTX Vertex Pharmaceuticals	Jun 10, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$641.00 41.85% Upside	+5.3%
APGE Apogee Therapeutics	Jun 10, 2026	HOLD	Strong Buy +28.7% avg upside 19 analysts	$89.00 1.57% Downside	+6.9%
AMGN Amgen	Jun 05, 2026	BUY	Buy -11.6% avg upside 57 analysts	$389.00 15.25% Upside	-3.4%
ELVN Enliven Therapeutics	Jun 04, 2026	BUY	Strong Buy +7.1% avg upside 14 analysts	$59.00 30.78% Upside	+22.4%
RLAY Relay Therapeutics	Jun 02, 2026	BUY	Strong Buy +26.4% avg upside 19 analysts	$22.00 38.63% Upside	+1.0%
PFS Provident Financial Services	Jun 01, 2026	BUY	Strong Buy +34.4% avg upside 16 analysts	$41.00 80.39% Upside	+4.3%
REGN Regeneron	May 18, 2026	BUY	Strong Buy +26.9% avg upside 57 analysts	$968.00 58.62% Upside	-3.3%
BIIB Biogen	May 15, 2026	BUY	Strong Buy +25.1% avg upside 51 analysts	$250.00 27.19% Upside	+3.0%
IMNM Immunome	May 13, 2026	BUY	Strong Buy +83.0% avg upside 16 analysts	$35.00 86.70% Upside	-16.5%
ANNX Annexon Biosciences	May 12, 2026	HOLD	Strong Buy +181.2% avg upside 13 analysts	$7.00 42.92% Upside	-5.9%
BMRN BioMarin Pharmaceutical	May 11, 2026	HOLD	Strong Buy +72.8% avg upside 52 analysts	$69.00 26.18% Upside	+4.6%
FDMT 4D Molecular Therapeutics	May 08, 2026	BUY	Strong Buy +265.2% avg upside 15 analysts	$33.00 241.53% Upside	-9.8%
GILD Gilead Sciences	May 08, 2026	HOLD	Strong Buy -4.8% avg upside 66 analysts	$130.00 4.95% Upside	-5.1%
VTRS Viatris	May 04, 2026	HOLD	Buy +48.4% avg upside 21 analysts	$16.00 4.16% Upside	+4.2%
SMMT Summit Therapeutics	May 01, 2026	BUY	Strong Buy +112.6% avg upside 27 analysts	$41.00 198.18% Upside	-13.9%
TEVA Teva Pharmaceutical	Apr 30, 2026	BUY	Buy -6.6% avg upside 39 analysts	$50.00 58.84% Upside	-7.2%
ALNY Alnylam Pharma	Apr 30, 2026	BUY	Strong Buy +23.6% avg upside 51 analysts	$550.00 97.75% Upside	-8.6%
RAPP Rapport Therapeutics, Inc.	Apr 21, 2026	BUY	Strong Buy +45.9% avg upside 12 analysts	$51.00 36.59% Upside	-0.2%
GENB Generate Biomedicines, Inc.	Apr 09, 2026	BUY	Strong Buy +75.3% avg upside 6 analysts	$26.00 79.53% Upside	·
RARE Ultragenyx Pharmaceutical	Mar 24, 2026	HOLD	Strong Buy +142.1% avg upside 36 analysts	$25.00 8.85% Downside	+24.9%
TSHA Taysha Gene Therapies	Mar 19, 2026	BUY	Strong Buy +102.5% avg upside 21 analysts	$11.00 71.43% Upside	+35.8%
SRPT Sarepta Therapeutics	Feb 25, 2026	HOLD	Buy +244.5% avg upside 49 analysts	$17.00 3.08% Downside	-17.0%
IONS Ionis Pharmaceuticals	Feb 25, 2026	HOLD	Strong Buy +13.3% avg upside 43 analysts	$72.00 2.79% Downside	-9.4%
RCUS Arcus Biosciences	Oct 30, 2025	HOLD	Strong Buy +38.0% avg upside 20 analysts	$16.00 34.23% Downside	+19.5%
ACAD ACADIA Pharmaceuticals	Aug 07, 2025	SELL	Strong Buy +65.9% avg upside 42 analysts	$17.00 21.43% Downside	+11.5%
ALF Centurion Acquisition Corp. Class A	Aug 07, 2025	HOLD	Hold +76.1% avg upside 1 analyst	$19.00 76.08% Upside	+2.9%
CRSP Crispr Therapeutics AG	Aug 05, 2025	HOLD	Buy +39.1% avg upside 41 analysts	$48.00 11.16% Downside	-2.7%
DNLI Denali Therapeutics	Jan 28, 2025	BUY	Strong Buy +60.2% avg upside 24 analysts	$40.00 71.66% Upside	-11.3%
ATRA Atara Biotherapeutics	Dec 19, 2024	HOLD	Buy +79.6% avg upside 18 analysts	—	+72.9%
RCKT Rocket Pharmaceuticals	Apr 02, 2024	HOLD	Buy +393.7% avg upside 29 analysts	$39.00 1064.08% Upside	-75.5%
SNDX Syndax Pharmaceuticals	Mar 05, 2024	BUY	Strong Buy +88.8% avg upside 27 analysts	$30.00 57.96% Upside	-36.9%
ADPT Adaptive Biotechnologies	Feb 16, 2024	HOLD	Strong Buy +19.9% avg upside 14 analysts	$5.00 71.41% Downside	+116.4%
BBIO BridgeBio Pharma	Jan 08, 2024	BUY	Strong Buy +38.7% avg upside 34 analysts	—	-24.0%
BMY Bristol-Myers Squibb	Jan 05, 2024	BUY	Buy +9.1% avg upside 42 analysts	—	+13.7%
RPRX Royalty Pharma	Jul 31, 2023	BUY	Strong Buy +4.2% avg upside 15 analysts	$53.00 0.01% Upside	-7.6%
EDIT Editas Medicine	Jun 12, 2023	SELL	Buy +407.9% avg upside 33 analysts	$7.00 160.32% Upside	+39.2%
CNTA Centessa Pharmaceuticals	May 15, 2023	HOLD	Buy -14.4% avg upside 19 analysts	$4.25 89.32% Downside	+89.4%
ALLO Allogene Therapeutics	Mar 01, 2023	BUY	Strong Buy +662.1% avg upside 28 analysts	$31.00 1449.94% Upside	-22.1%
ADSK Autodesk	Feb 24, 2023	BUY	Strong Buy +57.1% avg upside 44 analysts	$225.00 16.09% Upside	+33.6%
PRME Prime Medicine, Inc.	Nov 14, 2022	HOLD	Strong Buy +209.6% avg upside 16 analysts	$22.00 581.21% Upside	-63.9%
LYEL Lyell Immunopharma	Nov 11, 2022	HOLD	Buy +96.2% avg upside 10 analysts	$7.00 45.09% Downside	-63.5%
DTIL Precision BioSciences	Nov 10, 2022	HOLD	Strong Buy +247.1% avg upside 12 analysts	$1.00 85.32% Downside	-72.5%
RXRX Recursion Pharmaceuticals	Nov 09, 2022	HOLD	Buy +146.1% avg upside 12 analysts	$9.00 178.67% Upside	-48.9%
SANA Sana Biotechnology	Nov 03, 2022	HOLD	Strong Buy +214.8% avg upside 14 analysts	$6.00 90.47% Upside	-29.4%
PASG Passage Bio	Mar 04, 2021	BUY	Buy +214.0% avg upside 14 analysts	$30.00 436.64% Upside	-84.9%
MDGL Madrigal Pharmaceuticals	Mar 01, 2021	HOLD	Strong Buy -5.8% avg upside 31 analysts	$131.00 74.01% Downside	-16.6%
CLLS Cellectis SA	Nov 09, 2020	SELL	Strong Buy +573.5% avg upside 16 analysts	$11.00 269.13% Upside	+37.4%
RLMD Relmada Therapeutics	Oct 28, 2020	HOLD	Buy +105.6% avg upside 15 analysts	$40.00 494.39% Upside	-26.1%
ARWR Arrowhead Pharmaceuticals	May 08, 2020	HOLD	Strong Buy -19.2% avg upside 26 analysts	$47.00 42.55% Downside	+94.4%
SLDB Solid Biosciences	Nov 13, 2019	SELL	Strong Buy +90.3% avg upside 23 analysts	$2.00 76.07% Downside	-3.6%
UTHR United Therapeutics	Oct 29, 2013	HOLD	Buy -18.7% avg upside 26 analysts	$76.00 85.76% Downside	+51.0%
FBIO Fortress Biotech	Oct 15, 2013	HOLD	Strong Buy +164.2% avg upside 12 analysts	$2.00 33.05% Downside	+7.0%
ANTH Anthera Pharmaceuticals	Dec 02, 2011	BUY	Buy +472857042.9% avg upside 9 analysts	$13.00 1299999900.06% Upside	·

🔒 53 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Salveen Richter — Frequently Asked Questions

How accurate are Salveen Richter's stock ratings?

Based on the calls 13Foresight could measure, about 51% of Salveen's ratings were profitable over a one-year hold, with an average return of +0.7% per rating, or -11.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Salveen ranked on 13Foresight?

Salveen Richter is currently ranked #2149 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Salveen cover?

Salveen most recently has ratings on QURE, MRNA, INCY, AGIO, NTLA, VRTX, APGE, AMGN, ELVN, RLAY, PFS, REGN and 46 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!